# Lupus Erythematosus, Systemic trials: 279 new since Nov 2024

Updated November 6, 2026.

279 clinical studies in Lupus Erythematosus, Systemic were first posted on ClinicalTrials.gov from November 12, 2024 to November 6, 2026; 118 have an industry sponsor and 227 are recruiting or about to. The newest, NCT07923747, was posted on November 6, 2026: An Ascending Dose Study of DKB903 in Participants With Rheumatoid Arthritis (RA) and Participants With... (Novartis Pharmaceuticals).

## The full list

New Lupus Erythematosus, Systemic clinical trials: 279 rows for $13.95, first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Enrollment, Enrollment type, Location countries, Central contact, Contact phone, Contact email, Last update posted, Read on, Source. The new rows each week by email, about 10 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (central contact, contact phone, contact email, sponsor class, condition groups (MeSH), interventions and 5 more), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/condition/lupus-erythematosus-systemic

SpecStream is the live web data engine for teams and agents. It reads every new study on ClinicalTrials.gov each morning, and this page is that reading. Ask for the conditions, phases or countries you follow and each new trial arrives in your sheet, CRM, Slack or agent with the sponsor, the sites and the listed contact.

- New trials: 279
- Industry sponsored: 118
- Recruiting or not yet: 227
- Latest posted: November 6, 2026

## Newest trials

The newest 100 of 279, each linked to its record. The full list holds every one with the sponsor class, interventions, start date and the central contact as the record prints it.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Countries | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 6, 2026 | NCT07923747 | An Ascending Dose Study of DKB903 in Participants With Rheumatoid Arthritis (RA) and Participants With Systemic Lupus Erythematosus (SLE) | Novartis Pharmaceuticals | Phase 1 | Not yet recruiting | Rheumatoid Arthritis and Systemic Lupus Erythematosus | 90 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07923747) |
| November 3, 2026 | NCT07913919 | Effect of Anifrolumab on Arterial Inflammation in Systemic Lupus Erythematosus Study | University of Cambridge | Not applicable | Recruiting | Systemic Lupus Erythematosus, Atherosclerosis Generalized | 15 | United Kingdom | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07913919) |
| October 30, 2026 | NCT07906145 | A Phase 1 Study of QLS2416 Injection in Participants With Autoimmune Diseases | Shanghai Qilu Pharmaceutical Research and Development Center LTD | Phase 1 | Not yet recruiting | Systemic Lupus Erythematosus, Rheumatoid Arthritis (RA), Primary Sjögren's Syndrome (pSS), Systemic Sclerosis (SSc) | 76 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07906145) |
| October 29, 2026 | NCT07902622 | Pakistan Arthritis and Connective Tissue Disease Network - Systemic Lupus Erythematosus | Foundation University Islamabad | Observational | Recruiting | SLE - Systemic Lupus Erythematosus | 3,000 | Pakistan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07902622) |
| October 28, 2026 | NCT07901764 | MYTP01 for Immune-Mediated Diseases | Zhejiang Provincial People's Hospital | Not applicable | Not yet recruiting | IgA Nephropathy, Kidney Transplant Recipients, Lupus Nephritis, Primary Membranous Nephropathy, ANCA-associated... | 160 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07901764) |
| October 28, 2026 | NCT07901634 | Association of Inflammatory Biomarkers and Ferritin With Severity of Pediatric Systemic Lupus Erythematosus Patients | Desy Wulandari | Observational | Not yet recruiting | Lupus Erythematosus, Systemic | 62 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07901634) |
| October 23, 2026 | NCT07892651 | MENA/Levant Epidemiological, Registry of Immunological & Clinical Traits (MERIT) | Axiom Bioregistry | Observational | Not yet recruiting | Antiphospholipid (aPL)-Positive, Rheumatic Arthritis, Celiac Disease, Focal Segmental Glomerulosclerosis (FSGS)... | 5,000 | Jordan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07892651) |
| October 14, 2026 | NCT07873931 | A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases | Bristol-Myers Squibb | Phase 1 | Not yet recruiting | Systemic Lupus Erythematosus, Sjögren's Disease, Rheumatoid Arthritis, Idiopathic Inflammatory Myopathies, Systemic... | 60 | Belgium, France, Germany, Netherlands, Poland, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07873931) |
| October 9, 2026 | NCT07868289 | Effectiveness of Resonance Frequency Breathing Exercises in Patients With Systemic Lupus Erythematosus and Central Sensitization | Istanbul University - Cerrahpasa | Not applicable | Not yet recruiting | Systemic Lupus Erythematosus (SLE), Central Sensitization, Chronic Pain | 38 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07868289) |
| October 5, 2026 | NCT07858461 | Subclinical Gastrointestinal Involvement in Juvenile Systemic Lupus Erythematosus | Assiut University | Observational | Not yet recruiting | Systemic Lupus Erythematosus, Gastrointestinal Diseases | 60 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07858461) |
| October 2, 2026 | NCT07855302 | CD19 CAR-T Therapy for Refractory Childhood-Onset Systemic Lupus Erythematosus | Seoul National University Hospital | Phase 1 | Recruiting | Childhood-Onset Systemic Lupus Erythematosus, Refractory SLE, CD19 CAR-T Cell Therapy | 8 | South Korea | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07855302) |
| September 28, 2026 | NCT07844200 | The Primary Objective of the Trial is to Evaluate the Effect of the Addition of Belantamab Mafodotin to Standard of Care Therapy on the... | Medical Association for the Study of Cancer Biology and Treatment | Phase 2 | Not yet recruiting | SLE - Systemic Lupus Erythematosus | 12 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07844200) |
| September 25, 2026 | NCT07840573 | Feasibility and Performance of a Structured Video Telemedicine Program in Patients With Systemic Lupus Erythematous | Baylor College of Medicine | Not applicable | Completed | Systemic Lupus Erythematosus | 100 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07840573) |
| September 25, 2026 | NCT07840287 | A Long-Term Extension (LTE) Study Of Enpatoran In Cutaneous Manifestations Of Lupus With Or Without Systemic Disease \[Elowen-LTE\] | EMD Serono Research & Development Institute, Inc. | Phase 3 | Not yet recruiting | Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE) | 404 | Germany, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07840287) |
| September 23, 2026 | NCT07837544 | Diastolic Dysfunction and Inflammatory Biomarkers in Lupus Nephritis | Assiut University | Observational | Not yet recruiting | Lupus Nephritis, Diastolic Dysfunction, Systemic Lupus Erythematosus, Heart Failure, Diastolic | 90 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07837544) |
| September 21, 2026 | NCT07829614 | F182112 Phase Ib Clinical Study for the Treatment of Patients With Systemic Lupus Erythematosus | Shandong New Time Pharmaceutical Co., LTD | Phase 1 | Recruiting | Systemic Lupus Erythematosus (SLE) | 64 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07829614) |
| September 21, 2026 | NCT07829497 | Pain Phenotyping of Rheumatic Diseases - An Observational Study | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Observational | Recruiting | Rheumatic Diseases, Lupus Erythematosus, Systemic, Lupus Vasculitis, Central Nervous System, Arthritis... | 225 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07829497) |
| September 16, 2026 | NCT07823478 | HEALTH Home Urinalysis Testing | NYU Langone Health | Not applicable | Recruiting | Systemic Lupus Erythematosus | 160 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07823478) |
| September 9, 2026 | NCT07810569 | Ocular Surface Changes and Meibomian Gland Dysfunction in Rheumatologic Patients | Assiut University | Observational | Not yet recruiting | Meibomian Gland Dysfunction, Dry Eye Syndromes, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Sjogren's Syndrome... | 150 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07810569) |
| September 8, 2026 | NCT07805863 | Serum MPO-DNA Complexes as a Biomarker of Disease Activity in Systemic Lupus Erythematosus | Assiut University | Observational | Not yet recruiting | Systemic Lupus Erythematosus, Lupus Nephritis | 90 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07805863) |
| September 2, 2026 | NCT07800871 | FT839 in Autoimmune Diseases | Fate Therapeutics | Phase 1/2 | Recruiting | ANCA-Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Rheumatoid Arthritis (RA), Systemic Lupus... | 446 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07800871) |
| September 2, 2026 | NCT07799116 | Study to Evaluate the Safety and Preliminary Efficacy of CD19 CAR-T Cell Therapy (TranspoCART19) in Patients With Refractory Lupus Nephritis | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | Phase 1/2 | Recruiting | Lupus Nephritis, Lupus Nephritis (LN) | 10 | Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07799116) |
| August 27, 2026 | NCT07791199 | Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study Completers | Bristol-Myers Squibb | Phase 3 | Not yet recruiting | Systemic Lupus Erythematosus, Sjögren's Disease, Psoriasis, Psoriatic Arthritis | 2,300 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07791199) |
| August 24, 2026 | NCT07782450 | A Study to Learn About a Medicine Called PF-08154225 in Participants With Autoimmune Diseases | Pfizer | Phase 1/2 | Not yet recruiting | Systemic Lupus Erythematosus, Rheumatoid Arthritis, Idiopathic Inflammatory Myositis, Systemic Sclerosis | 54 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07782450) |
| August 21, 2026 | NCT07780045 | SII and SIRI as Prognostic Biomarkers in Lupus Nephritis | Assiut University | Observational | Not yet recruiting | Lupus Nephritis, Systemic Lupus Erythematosus, Kidney Diseases | 100 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07780045) |
| August 21, 2026 | NCT07778446 | A Study to Test CRT-402 in Refractory Autoimmune Disease | Myeloid Therapeutics | Phase 1/2 | Recruiting | Autoimmune Diseases, Systemic Lupus Erythematosus, Systemic Scleroderma, Myositis | 34 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07778446) |
| August 20, 2026 | NCT07775612 | Pain-Sleep in Rheumatic Disease | The Hospital for Sick Children | Not applicable | Not yet recruiting | Rheumatic Diseases, Arthritis, Lupus, Lupus Arthritis, Systemic Lupus Erythematosus, JIA, Dermatomyositis, Vasculitis... | 43 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07775612) |
| August 13, 2026 | NCT07763821 | Clinical Utility of Serum Ribonuclease 1(RNASE1) as a Biomarker of Lupus Nephritis. | Assiut University | Observational | Not yet recruiting | System Lupus Erythematosus(SLE) | 128 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07763821) |
| August 12, 2026 | NCT07760480 | Assessing Residual Inflammation and Macrophage Presence in Lupus Nephritis After 3 Months of Intensified Treatment With Prednisolone... | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Phase 4 | Recruiting | Lupus Nephritis, Systemic Lupus Erythematosus (SLE) | 55 | Netherlands | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07760480) |
| August 12, 2026 | NCT07760155 | A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Systemic Lupus Erythematosus | Shanghai Escugen Biotechnology Co., Ltd | Phase 2 | Not yet recruiting | Systemic Lupus Erythematosus (SLE) | 40 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07760155) |
| August 7, 2026 | NCT07751848 | A Study of Outcomes in Chinese Patients Treated With Anifrolumab Who Have Active Mod-severe Systemic Lupus Erythematosus | AstraZeneca | Phase 3 | Recruiting | Lupus Erythematosus, Systemic | 417 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07751848) |
| August 7, 2026 | NCT07751315 | A Study of QLS2404 Injection in Healthy Participants and Participants With Rheumatic Autoimmune Diseases | Qilu Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | Systemic Lupus Erythematosus, Primary Sjögren's Syndrome | 64 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07751315) |
| August 5, 2026 | NCT07748156 | SNC116 Therapy for Refractory Systemic Lupus Erythematosus | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Early phase 1 | Not yet recruiting | Systemic Lupus Erythematosus | 28 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07748156) |
| July 28, 2026 | NCT07732309 | A Study of ATG-201 in Adult Participants With Autoimmune Diseases | Antengene Biologics Limited | Phase 1 | Recruiting | Systemic Lupus Erythematosus, Systemic Sclerosis (SSc), Sjogren's Disease, Autoimmune Diseases | 149 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07732309) |
| July 28, 2026 | NCT07729826 | C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Lupus Nephritis Refractory to... | AbelZeta Inc. | Phase 2 | Not yet recruiting | Lupus Nephritis (LN), Systemic Lupus Erythematosus (SLE), Autoimmune Diseases | 50 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07729826) |
| July 23, 2026 | NCT07721363 | Obinutuzumab for Systemic Lupus Erythematosus Pure Membranous Nephropathy: a Phase II Trial | Assistance Publique - Hôpitaux de Paris | Phase 2 | Not yet recruiting | Lupus Nephritis, Membranous Nephropathy | 65 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07721363) |
| July 23, 2026 | NCT07721324 | Effect of Melatonin Administration on Systemic Lupus Erythematosus Patients | Ain Shams University | Phase 2/3 | Not yet recruiting | Therapy, Treatment | 64 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07721324) |
| July 22, 2026 | NCT07720310 | Anti-CD19 CAR-T Cell Therapy for Patients With Refractory Systemic Lupus Erythematosus | N.N. Alexandrov National Cancer Centre | Observational | Enrolling by invitation | System Lupus Erythematosus(SLE) | 12 | Belarus | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07720310) |
| July 22, 2026 | NCT07719140 | Childhood-onset Lupus Nephritis Initial Glucocorticoid-dose Harmonization Trial (LIGHT Trial) | Peking Union Medical College Hospital | Phase 4 | Recruiting | Childhood-onset Systemic Lupus Erythematosus, Lupus Nephritis (LN) | 198 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07719140) |
| July 7, 2026 | NCT07688980 | Study to Characterise Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Anifrolumab Administered Subcutaneously (SC) or... | AstraZeneca | Phase 1 | Not yet recruiting | Systemic Lupus Erythematosus | 92 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07688980) |
| July 1, 2026 | NCT07680010 | Modeling the Early Stages of Autoimmunity Through the Study of Immunological Thrombocytopenic Purpura and Juvenile Lupus | University Hospital, Bordeaux | Not applicable | Not yet recruiting | Immune Thrombocytopenic Purpura ( ITP ), Systemic Lupus Erythematosus (SLE) | 105 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07680010) |
| July 1, 2026 | NCT07679776 | Study on Early Visual Dysfunction in Patients With Systemic Lupus Erythematosus | The First Affiliated Hospital of Anhui Medical University | Observational | Enrolling by invitation | Systemic Lupus Erythematosus (SLE), Visual Function | 100 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07679776) |
| July 1, 2026 | NCT07678203 | Dapagliflozin to Reduce the Decline in Renal Function in Patients Newly Diagnosed With Lupus Nephritis | Hospital Civil Juan I. Menchaca | Phase 1/2 | Active not recruiting | Lupus Nephritis (LN), Chronic Kidney Disease, SGLT 2 Inhibitors, Systemic Lupus Erythematosus | 30 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07678203) |
| June 30, 2026 | NCT07676266 | A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy | The Affiliated Hospital of Qingdao University | Phase 1 | Not yet recruiting | Multiple Sclerosis (MS), Myasthenia Gravis (MG), Neuromyelitis Optica Spectrum Disorder, Systemic Lupus Erythematosus... | 18 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07676266) |
| June 29, 2026 | NCT07674147 | RD06-05 Universal CD19/BCMA CAR-T for Refractory Pediatric Autoimmune Diseases | The Children's Hospital of Zhejiang University School of Medicine | Early phase 1 | Not yet recruiting | Autoimmune Diseases, SLE - Systemic Lupus Erythematosus, SSc-Systemic Sclerosis, IIM- Idiopathic Inflammatory... | 30 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07674147) |
| June 24, 2026 | NCT07666711 | Biomarker Development for Autoimmune Disorders Involving the Kidneys | Oslo University Hospital | Observational | Recruiting | Lupus Nephritis, Systemic Lupus Erythematosus | 500 | Norway | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07666711) |
| June 22, 2026 | NCT07659704 | CD19-Directed CAR-T Cell Therapy in Refractory Systemic Lupus Erythematosus | University of Sao Paulo | Phase 1/2 | Not yet recruiting | Lupus Erythematosus, Systemic | 16 | Brazil | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07659704) |
| June 18, 2026 | NCT07657793 | Sirolimus in Patients With Systemic Lupus Erythematosus-Associated Immune Thrombocytopenia | Chinese SLE Treatment And Research Group | Phase 2/3 | Recruiting | Systemic Lupus Erythematosus, Immune Thrombocytopenia | 164 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07657793) |
| June 16, 2026 | NCT07649265 | A Trial in Healthy Adult Participants and Adults With Autoimmune Diseases to Test How HBM7020 is Tolerated and How it Behaves in the Body | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 1 | Recruiting | Rheumatoid Arthritis, Systemic Lupus Erythematosus, Systemic Sclerosis, Sjögren's Disease | 63 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07649265) |
| June 9, 2026 | NCT07636044 | Reduced Vaccine Response to HZ/su in SLE | Seoul National University Hospital | Observational | Recruiting | Vaccine Reaction, Zoster, Systemic Lupus Erythematosus | 80 | South Korea | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07636044) |
| June 5, 2026 | NCT07630714 | A Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to \< 18 Years... | AstraZeneca | Phase 2 | Recruiting | Systemic Lupus Erythematosus | 24 | Australia, Belgium, Chile, Israel, Japan, Netherlands, Peru, Philippines... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07630714) |
| June 5, 2026 | NCT07629596 | Evaluation of Safety, Pharmacokinetics and Pharmacodynamics of Arnovie101, an mRNA-LNP-Based In Vivo CAR-T Therapy, for the Treatment of B... | Circunited BioPharma (Shenzhen) Co., Ltd. | Early phase 1 | Recruiting | Systemic Lupus Erythematosus, Autoimmune Hemolytic Anemia (AIHA) | 5 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07629596) |
| June 5, 2026 | NCT07629583 | To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis | Genentech, Inc. | Phase 1 | Recruiting | Lupus Erythematosus, Systemic | 46 | Australia, Brazil, China, France, Italy, Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07629583) |
| June 3, 2026 | NCT07622251 | The Effect of Exercise on Cognitive Functions in Individuals With Systemic Lupus Erythematosus | Istanbul Galata University | Not applicable | Not yet recruiting | System Lupus Erythematosus(SLE) | 38 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07622251) |
| June 1, 2026 | NCT07617740 | IASO207 Injection for Active Refractory Systemic Lupus Erythematosus (SLE) | Peking University People's Hospital | Early phase 1 | Recruiting | REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS | 18 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07617740) |
| May 28, 2026 | NCT07611747 | Carotid Ultrasound-Based Strategy for Primary Prevention of Cardiovascular Events in Inflammatory Rheumatic Disease (PREVENER) | Instituto de Investigación Marqués de Valdecilla | Phase 4 | Recruiting | Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Axial Spondy, Systemic Lupus Erythematosus (SLE), Caridovascular... | 1,944 | Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07611747) |
| May 27, 2026 | NCT07607964 | A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous... | AbbVie | Phase 1 | Recruiting | Systemic Lupus Erythematosus, Rheumatoid Arthritis | 30 | Japan, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07607964) |
| May 20, 2026 | NCT07598396 | A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis | Hoffmann-La Roche | Phase 2 | Recruiting | Lupus, Systemic Lupus Erythematosus, Lupus Nephritis | 30 | Argentina, Brazil, Colombia, Italy, Mexico, South Africa | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07598396) |
| May 19, 2026 | NCT07596680 | CD19/BCMA-Targeted Universal CAR-T Cell Injection for the Treatment of Autoimmune Diseases | Nanjing Bioheng Biotech Co., Ltd. | Early phase 1 | Not yet recruiting | SLE - Systemic Lupus Erythematosus, Systemic Sclerosis, ANCA Associated Vasculitis, Idiopathic Inflammatory Myopathies... | 30 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07596680) |
| May 13, 2026 | NCT07583030 | A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Autoimmune Diseases | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Early phase 1 | Withdrawn | Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE), Relapsed/Refractory IgG4-Related Disease (r/r IgG4-RD)... | 0 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07583030) |
| May 8, 2026 | NCT07575347 | Periodontal Disease in Rare Renal Disorders (PERIO-RA-RE) | Stefan Lujinschi | Observational | Recruiting | Periodontal Disease, Periodontitis, CKD, Chronic Kidney Disease, Alport Syndrome, Fabry Disease, Lupus or SLE, Tuberous... | 100 | Romania | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07575347) |
| May 6, 2026 | NCT07570862 | A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis | Fate Therapeutics | Phase 2 | Recruiting | Lupus Nephritis, Systemic Lupus Erythematosus, SLE - Systemic Lupus Erythematosus, Lupus Nephritis - WHO Class III... | 53 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07570862) |
| April 30, 2026 | NCT07558850 | Exploratory Clinical Study of Anti-CD19/BCMA Universal CAR-T Cell Injection for the Treatment of Refractory Autoimmune Diseases | The First Affiliated Hospital with Nanjing Medical University | Not applicable | Recruiting | Rheumatoid Arthritis, Dermatomyositis, Systemic Lupus Erythematosus, Systemic Sclerosis | 72 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07558850) |
| April 29, 2026 | NCT07555626 | Mediterranean Diet and Gut Microbiota in Children With Systemic Lupus Erythematosus | TC Erciyes University | Not applicable | Not yet recruiting | Systemic Lupus Erythematosus (SLE) | 60 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07555626) |
| April 22, 2026 | NCT07544225 | Study Investigating the Safety of Anti-CD19 CAR-T Cells Therapy Produced at Gustave Roussy for Adults With Severe and Refractory Systemic... | Gustave Roussy, Cancer Campus, Grand Paris | Phase 1 | Not yet recruiting | Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Sjogren's Disease With Dry Eyes, Systemic Sclerosis... | 6 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07544225) |
| April 20, 2026 | NCT07538154 | A Clinica Study of SCTC21C in Participants With Systemic Lupus Erythematosus | Sinocelltech Ltd. | Phase 1/2 | Not yet recruiting | Systemic Lupus Erythematosus (SLE) | 159 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07538154) |
| April 13, 2026 | NCT07526350 | MTS109 in Patients With Refractory Autoimmune Diseases | Shanghai Changzheng Hospital | Early phase 1 | Recruiting | Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies, Systemic Sclerosis (SSc), ANCA-Associated Vasculitis... | 15 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07526350) |
| April 13, 2026 | NCT07523542 | SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory Lupus | Beijing Biotech | Phase 1/2 | Recruiting | REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS, Lupus Nephritis | 24 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07523542) |
| April 13, 2026 | NCT07523282 | Safety and Preliminary Efficacy of HN2302 in Patients With Autoimmune Diseases | Shenzhen MagicRNA Biotechnology Co., Ltd | Phase 1 | Not yet recruiting | Autoimmune Disease, Systemic Lupus Erythematosus, Systemic Sclerosis (SSc) | 12 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07523282) |
| April 8, 2026 | NCT07517536 | CHT105 for the Treatment of Refractory Lupus Nephritis | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Not applicable | Enrolling by invitation | Systemic Lupus Erythematosus, Lupus Nephritis | 14 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07517536) |
| April 8, 2026 | NCT07516639 | First-in-Human Study of ISH0613: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics | SUNHO（China）BioPharmaceutical CO., Ltd. | Phase 1 | Not yet recruiting | Healthy Subjects (HS), SLE (Systemic Lupus) | 26 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07516639) |
| April 7, 2026 | NCT07515638 | Immun4Cure Cohort of Autoimmune Diseases | University Hospital, Montpellier | Observational | Recruiting | Rheumatoid Arthritis, Systemic Lupus Erythematosus, Systemic Sclerosis, Healthy Adult Volunteers | 500 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07515638) |
| April 7, 2026 | NCT07515014 | A Study of E6742 in Participants With Systemic Lupus Erythematosus | Eisai Co., Ltd. | Phase 2 | Recruiting | Systemic Lupus Erythematosus | 256 | China, Japan, South Korea, Taiwan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07515014) |
| April 6, 2026 | NCT07512947 | Study of YKST02 Alone or in Combination With YK012 in Patients With Active or Refractory Systemic Lupus Erythematosus | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 1 | Not yet recruiting | System Lupus Erythematosus(SLE) | 30 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07512947) |
| April 3, 2026 | NCT07509892 | A Clinical Trial on the Efficacy and Safety of TQH3906 in the Treatment of Systemic Lupus Erythematosus | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 2 | Recruiting | Systemic Lupus Erythematosus | 198 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07509892) |
| March 25, 2026 | NCT07493655 | Therapeutic Drug Monitoring of Mycophenolate Mofetil in Lupus Nephritis | Federal University of Maranhao | Not applicable | Not yet recruiting | Systemic Lupus Erythematosus, Lupus Nephritis, Drug Monitoring, Mycophenolic Acid | 100 | Brazil | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07493655) |
| March 24, 2026 | NCT07490275 | Allogeneic CD19/BCMA-Targeted CAR-γδT Cell Therapy: Safety and Preliminary Pharmacodynamics in Relapsed/Refractory Autoimmune Diseases | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 | Not yet recruiting | Refractory/Relapsed Systemic Lupus Erythematosus, Refractory / Relapsed / Progressive Systemic Sclerosis, Refractory /... | 9 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07490275) |
| March 24, 2026 | NCT07490041 | Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA CAR-NK Cell Injection for the Treatment of Refractory Pediatric... | The Children's Hospital of Zhejiang University School of Medicine | Early phase 1 | Recruiting | Rheumatic Diseases, Pediatric Rheumatological Condition (i.e., Arthritis, SLE, Kawasaki's Disaese), Systemic Lupus... | 36 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07490041) |
| March 19, 2026 | NCT07483541 | Identification of Modifiable Sleep-related Factors in Patients With Systemic Lupus Erythematosus. | Investigación en Hemofilia y Fisioterapia | Observational | Not yet recruiting | Lupus Erythematosus | 250 | Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07483541) |
| March 19, 2026 | NCT07483346 | IASO-782 in Systemic Lupus Erythematosus | Shanghai IASO Biotechnology Co., Ltd | Phase 1 | Recruiting | SLE - Systemic Lupus Erythematosus | 20 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07483346) |
| March 18, 2026 | NCT07481214 | Lupus Walking Intervention to Address Fatigue/Quality of Life | University of California, San Francisco | Not applicable | Completed | System Lupus Erythematosus(SLE) | 101 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07481214) |
| March 13, 2026 | NCT07470151 | Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not applicable | Recruiting | System Lupus Erythematosus(SLE), Scleroderma, Myasthenia Gravis (MG) | 12 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07470151) |
| March 4, 2026 | NCT07447986 | To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus Erythematosus | Hangzhou Sumgen Biotech Co., Ltd. | Phase 2 | Recruiting | Systemic Lupus Erythematosus (SLE) | 120 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07447986) |
| March 2, 2026 | NCT07444307 | A Clinical Study of Dual-Target, Universal CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus | Hangzhou Qihan Biotech Co., Ltd. | Phase 1 | Recruiting | Systemic Lupus Erythematosus (SLE) | 18 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07444307) |
| February 27, 2026 | NCT07439029 | YTS109 in Pediatric Relapsed/Refractory Autoimmune Diseases | Children's Hospital of Fudan University | Phase 1 | Not yet recruiting | Systemic Lupus Erythematosus (SLE), Diffuse Systemic Sclerosis, Idiopathic Inflammatory Myopathies (IIMs), ANCA... | 12 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07439029) |
| February 27, 2026 | NCT07438496 | A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus | Janssen Research & Development, LLC | Phase 3 | Recruiting | Lupus Erythematosus, Systemic | 600 | Argentina, Australia, Brazil, Bulgaria, China, Czechia, Denmark, Finland... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07438496) |
| February 25, 2026 | NCT07432334 | CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus | Vinmec Research Institute of Stem Cell and Gene Technology | Phase 1 | Recruiting | Refractory Systemic Lupus Erythematosus | 8 | Vietnam | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07432334) |
| February 25, 2026 | NCT07431775 | Saphnelo Use in Females of Child-bearing Potential | AstraZeneca | Observational | Not yet recruiting | Systemic Lupus Erythematosus | 26,000,000 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07431775) |
| February 24, 2026 | NCT07430306 | A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus... | AstraZeneca | Phase 3 | Recruiting | Systemic Lupus Erythematosus | 245 | Canada, France, Germany, Italy, Mexico, Poland, Spain, Taiwan, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07430306) |
| February 23, 2026 | NCT07425730 | Early Myocardial Dysfunction Helps Identify Severe Refractory Pediatric Lupus | Shanghai Jiao Tong University School of Medicine | Observational | Recruiting | Systemic Lupus Erythematosus (SLE) | 60 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07425730) |
| February 20, 2026 | NCT07424261 | NIS to Examine Disease Activity in SLE Patients Treated With Subcutaneous Anifrolumab in Routine Care | AstraZeneca | Observational | Recruiting | Lupus Erythematosus, Systemic | 125 | Germany | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07424261) |
| February 17, 2026 | NCT07413341 | A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases | Therorna | Phase 1 | Recruiting | Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome (SS), Systemic Sclerosis (SSc), Inflammatory Myopathy, ANCA... | 12 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07413341) |
| February 13, 2026 | NCT07410377 | UCAR T-cell Therapy Targeting CD19/ BCMA(QT-019C) in Patients With Relapse/ Refractory Autoimmune Diseases | The Affiliated Hospital of Xuzhou Medical University | Early phase 1 | Withdrawn | Systemic Lupus Erythematosus, Inflammatory Myopathy | 0 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07410377) |
| February 13, 2026 | NCT07409181 | A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE) | Boehringer Ingelheim | Phase 2 | Recruiting | Systemic Lupus Erythematosus | 405 | Argentina, Australia, Brazil, Bulgaria, China, Colombia, Croatia, Germany... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07409181) |
| February 13, 2026 | NCT07408908 | Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic (PK/PD) Profile of ACT100 in Healthy Participants.. | Xiamen Amoytop Biotech Co., Ltd. | Phase 1 | Not yet recruiting | Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus | 48 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07408908) |
| February 12, 2026 | NCT07405970 | A Phase 3 Clinical Study of MIL62 in Systemic Lupus Erythematosus | Beijing Mabworks Biotech Co., Ltd. | Phase 3 | Recruiting | Systemic Lupus Erythematosus | 316 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07405970) |
| February 11, 2026 | NCT07403097 | Study of CD19 CAR-T Therapy for Refractory SLE | Chongqing Precision Biotech Co., Ltd | Phase 1 | Recruiting | Systemic Lupus Erythematosus | 18 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07403097) |
| February 10, 2026 | NCT07398885 | Assessing the Impact of Herbal Supplement on Fatigue and Disease Activity in SLE: Results From an 8-Week Randomized Trial | University Tunis El Manar | Not applicable | Completed | System; Lupus Erythematosus | 59 | Tunisia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07398885) |
| February 9, 2026 | NCT07397728 | " TREX1 Gene Mutations and Their Role in Systemic Lupus Erythematosus | South Valley University | Observational | Recruiting | Systemic Lupus Erythematosus | 90 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07397728) |
| February 6, 2026 | NCT07394361 | The Effect of Clinical Pilates Training on Fatigue, Emotional State, Functional Capacity, Sleep and Quality of Life in Women With Systemic... | Emir İbrahim IŞIK | Not applicable | Enrolling by invitation | Lupus Erythematosus, Systemic | 30 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07394361) |

## Sponsors posting most

| Sponsor | New trials | Latest |
| --- | --- | --- |
| AstraZeneca | 16 | August 7, 2026 |
| Assiut University | 10 | October 5, 2026 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 7 | May 13, 2026 |
| The Children's Hospital of Zhejiang University School of Medicine | 6 | June 29, 2026 |
| China Immunotech (Beijing) Biotechnology Co., Ltd. | 5 | November 19, 2025 |
| Bristol-Myers Squibb | 4 | October 14, 2026 |
| Assistance Publique - Hôpitaux de Paris | 4 | July 23, 2026 |
| Chinese SLE Treatment And Research Group | 4 | June 18, 2026 |
| Peking University People's Hospital | 4 | June 1, 2026 |
| Institute of Hematology & Blood Diseases Hospital, China | 4 | March 24, 2026 |
| Chongqing Precision Biotech Co., Ltd | 4 | February 11, 2026 |
| Tongji Hospital | 4 | January 14, 2026 |
| Universitas Sriwijaya | 4 | July 24, 2025 |
| EMD Serono Research & Development Institute, Inc. | 3 | September 25, 2026 |
| NYU Langone Health | 3 | September 16, 2026 |
| The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 3 | August 5, 2026 |
| Sohag University | 3 | January 20, 2026 |
| CytoCares Inc | 3 | September 26, 2025 |
| Seoul National University Hospital | 2 | October 2, 2026 |
| Fate Therapeutics | 2 | September 2, 2026 |

## By phase

| Phase | New trials | Latest |
| --- | --- | --- |
| [Phase 1](https://specstream.ai/data/clinical-trials/phase/phase-1) | 79 | November 6, 2026 |
| [Observational](https://specstream.ai/data/clinical-trials/phase/observational) | 66 | October 29, 2026 |
| [Not applicable](https://specstream.ai/data/clinical-trials/phase/not-applicable) | 43 | November 3, 2026 |
| [Phase 2](https://specstream.ai/data/clinical-trials/phase/phase-2) | 27 | September 28, 2026 |
| [Early phase 1](https://specstream.ai/data/clinical-trials/phase/early-phase-1) | 25 | August 5, 2026 |
| [Phase 1/2](https://specstream.ai/data/clinical-trials/phase/phase-1-2) | 20 | September 2, 2026 |
| [Phase 3](https://specstream.ai/data/clinical-trials/phase/phase-3) | 10 | September 25, 2026 |
| [Phase 4](https://specstream.ai/data/clinical-trials/phase/phase-4) | 7 | August 12, 2026 |
| [Phase 2/3](https://specstream.ai/data/clinical-trials/phase/phase-2-3) | 2 | July 23, 2026 |

## By country

| Country | New trials | Latest |
| --- | --- | --- |
| [China](https://specstream.ai/data/clinical-trials/country/china) | 118 | October 28, 2026 |
| [United States](https://specstream.ai/data/clinical-trials/country/united-states) | 54 | October 14, 2026 |
| [Spain](https://specstream.ai/data/clinical-trials/country/spain) | 24 | September 2, 2026 |
| [France](https://specstream.ai/data/clinical-trials/country/france) | 23 | October 14, 2026 |
| [Germany](https://specstream.ai/data/clinical-trials/country/germany) | 16 | October 14, 2026 |
| [Brazil](https://specstream.ai/data/clinical-trials/country/brazil) | 16 | June 22, 2026 |
| [Australia](https://specstream.ai/data/clinical-trials/country/australia) | 15 | August 21, 2026 |
| [Italy](https://specstream.ai/data/clinical-trials/country/italy) | 15 | June 5, 2026 |
| [Japan](https://specstream.ai/data/clinical-trials/country/japan) | 12 | June 5, 2026 |
| [United Kingdom](https://specstream.ai/data/clinical-trials/country/united-kingdom) | 11 | November 3, 2026 |
| [Poland](https://specstream.ai/data/clinical-trials/country/poland) | 10 | October 14, 2026 |
| [Belgium](https://specstream.ai/data/clinical-trials/country/belgium) | 9 | October 14, 2026 |
| [Romania](https://specstream.ai/data/clinical-trials/country/romania) | 9 | May 8, 2026 |
| [Taiwan](https://specstream.ai/data/clinical-trials/country/taiwan) | 9 | April 7, 2026 |
| [Canada](https://specstream.ai/data/clinical-trials/country/canada) | 9 | February 24, 2026 |
| [South Korea](https://specstream.ai/data/clinical-trials/country/south-korea) | 8 | October 2, 2026 |
| [Egypt](https://specstream.ai/data/clinical-trials/country/egypt) | 8 | July 23, 2026 |
| [Israel](https://specstream.ai/data/clinical-trials/country/israel) | 8 | June 5, 2026 |
| [Bulgaria](https://specstream.ai/data/clinical-trials/country/bulgaria) | 7 | February 27, 2026 |
| [Netherlands](https://specstream.ai/data/clinical-trials/country/netherlands) | 6 | October 14, 2026 |
| [Turkey (Türkiye)](https://specstream.ai/data/clinical-trials/country/turkey-t-rkiye) | 6 | October 9, 2026 |
| [Argentina](https://specstream.ai/data/clinical-trials/country/argentina) | 6 | May 20, 2026 |
| [Mexico](https://specstream.ai/data/clinical-trials/country/mexico) | 5 | July 1, 2026 |
| [South Africa](https://specstream.ai/data/clinical-trials/country/south-africa) | 5 | May 20, 2026 |
| [Indonesia](https://specstream.ai/data/clinical-trials/country/indonesia) | 5 | September 19, 2025 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Condition groups are the MeSH terms ClinicalTrials.gov assigns to each study's conditions; a study with several is in several groups. Sponsor class is the register's class of the lead sponsor. The central contact is in the full list only as the record prints it.

Free to reuse with credit to SpecStream under [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/).